TY  - JOUR

T1  - Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development

JO  - Endocrine, Metabolic & Immune Disorders - Drug Targets

UR  - https://doi.org/10.2174/187153009788452453

PY  - 2009/06/01

AU  - Rutella S

AU  - Bonanno G

AU  - De Cristofaro R

ED  - 

DO  - DOI: 10.2174/187153009788452453

PB  - Bentham Science Publishers Ltd.

VL  - 9

IS  - 2

SP  - 151

EP  - 177

Y2  - 2026/02/25

ER  -